Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP322452.RAWRrtmJmvlnwiKP44WFJ9-CqgSRzABUjQUi5OgySrWJ8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP322452.RAWRrtmJmvlnwiKP44WFJ9-CqgSRzABUjQUi5OgySrWJ8130_assertion type Assertion NP322452.RAWRrtmJmvlnwiKP44WFJ9-CqgSRzABUjQUi5OgySrWJ8130_head.
- NP322452.RAWRrtmJmvlnwiKP44WFJ9-CqgSRzABUjQUi5OgySrWJ8130_assertion description "[Furthermore, the use of the FDA-approved drug trifluoperazine hydrochloride (TFP), which has been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib resistance through modulation of the KLF6/FOXO1 signaling cascade in both cell culture and xenograft models of lung adenocarcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP322452.RAWRrtmJmvlnwiKP44WFJ9-CqgSRzABUjQUi5OgySrWJ8130_provenance.
- NP322452.RAWRrtmJmvlnwiKP44WFJ9-CqgSRzABUjQUi5OgySrWJ8130_assertion evidence source_evidence_literature NP322452.RAWRrtmJmvlnwiKP44WFJ9-CqgSRzABUjQUi5OgySrWJ8130_provenance.
- NP322452.RAWRrtmJmvlnwiKP44WFJ9-CqgSRzABUjQUi5OgySrWJ8130_assertion SIO_000772 22653055 NP322452.RAWRrtmJmvlnwiKP44WFJ9-CqgSRzABUjQUi5OgySrWJ8130_provenance.
- NP322452.RAWRrtmJmvlnwiKP44WFJ9-CqgSRzABUjQUi5OgySrWJ8130_assertion wasDerivedFrom befree-20150227 NP322452.RAWRrtmJmvlnwiKP44WFJ9-CqgSRzABUjQUi5OgySrWJ8130_provenance.
- NP322452.RAWRrtmJmvlnwiKP44WFJ9-CqgSRzABUjQUi5OgySrWJ8130_assertion wasGeneratedBy ECO_0000203 NP322452.RAWRrtmJmvlnwiKP44WFJ9-CqgSRzABUjQUi5OgySrWJ8130_provenance.